Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance. / Kalsen, Anders; Hostrup, Morten; Karlsson, Sebastian; Hemmersbach, Peter; Bangsbo, Jens; Backer, Vibeke.

I: Journal of Applied Physiology, Bind 117, Nr. 10, 2014, s. 1180-1187.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Kalsen, A, Hostrup, M, Karlsson, S, Hemmersbach, P, Bangsbo, J & Backer, V 2014, 'Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance', Journal of Applied Physiology, bind 117, nr. 10, s. 1180-1187. https://doi.org/10.1152/japplphysiol.00635.2014

APA

Kalsen, A., Hostrup, M., Karlsson, S., Hemmersbach, P., Bangsbo, J., & Backer, V. (2014). Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance. Journal of Applied Physiology, 117(10), 1180-1187. https://doi.org/10.1152/japplphysiol.00635.2014

Vancouver

Kalsen A, Hostrup M, Karlsson S, Hemmersbach P, Bangsbo J, Backer V. Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance. Journal of Applied Physiology. 2014;117(10):1180-1187. https://doi.org/10.1152/japplphysiol.00635.2014

Author

Kalsen, Anders ; Hostrup, Morten ; Karlsson, Sebastian ; Hemmersbach, Peter ; Bangsbo, Jens ; Backer, Vibeke. / Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance. I: Journal of Applied Physiology. 2014 ; Bind 117, Nr. 10. s. 1180-1187.

Bibtex

@article{26a0a99df7514e47bbe3d984bb5e13c2,
title = "Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance",
abstract = "In a randomized double-blind crossover design, we investigated the effect of the beta2-agonist terbutaline on endurance performance and substrate utilization in nine moderately trained males (maximum oxygen uptake (VO2max): 58.9±3.1 mL min(-1) kg(-1)). Subjects performed 60 min of submaximal exercise (65-70% of VO2max) immediately followed by a 300-kcal time trial with inhalation of either terbutaline (TER) or placebo (PLA). Pulmonary gas exchange was measured during the submaximal exercise and muscle biopsies were collected before and after the exercise bouts. Time trial performance was not different between PLA and TER (1054±125 vs. 1072±145 s). During the submaximal exercise, respiratory exchange ratio, glycogen breakdown (PLA: 195±28; TER: 266±32 mmol kg dw(-1)) and muscle lactate accumulation (PLA: 13.2±1.2; TER: 20.3±1.6 mmol kg dw(-1)) were higher (P<0.05) with TER than PLA. There was no difference between PLA and TER in net muscle glycogen utilization and lactate accumulation during the time trial. IMTG did not change with treatment or exercise. PDH-E1α Ser(293) and Ser(300) phosphorylation were lower (P<0.05) before the submaximal exercise with TER than PLA with no difference after the submaximal exercise and the time trial. Before the submaximal exercise, ACC2 Ser(221) phosphorylation was higher (P<0.05) with TER than PLA. There was no difference in αAMPK Thr(172) phosphorylation between treatments. The present study suggests that beta2-agonists do not enhance 300-kcal time trial performance, but increase carbohydrate metabolism in skeletal muscles during submaximal exercise independent of AMPK and ACC phosphorylation, and that this effect diminishes as drug exposure time, exercise duration and intensity are increased.",
author = "Anders Kalsen and Morten Hostrup and Sebastian Karlsson and Peter Hemmersbach and Jens Bangsbo and Vibeke Backer",
note = "CURIS 2014 NEXS 293",
year = "2014",
doi = "10.1152/japplphysiol.00635.2014",
language = "English",
volume = "117",
pages = "1180--1187",
journal = "Journal of Applied Physiology",
issn = "8750-7587",
publisher = "American Physiological Society",
number = "10",

}

RIS

TY - JOUR

T1 - Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance

AU - Kalsen, Anders

AU - Hostrup, Morten

AU - Karlsson, Sebastian

AU - Hemmersbach, Peter

AU - Bangsbo, Jens

AU - Backer, Vibeke

N1 - CURIS 2014 NEXS 293

PY - 2014

Y1 - 2014

N2 - In a randomized double-blind crossover design, we investigated the effect of the beta2-agonist terbutaline on endurance performance and substrate utilization in nine moderately trained males (maximum oxygen uptake (VO2max): 58.9±3.1 mL min(-1) kg(-1)). Subjects performed 60 min of submaximal exercise (65-70% of VO2max) immediately followed by a 300-kcal time trial with inhalation of either terbutaline (TER) or placebo (PLA). Pulmonary gas exchange was measured during the submaximal exercise and muscle biopsies were collected before and after the exercise bouts. Time trial performance was not different between PLA and TER (1054±125 vs. 1072±145 s). During the submaximal exercise, respiratory exchange ratio, glycogen breakdown (PLA: 195±28; TER: 266±32 mmol kg dw(-1)) and muscle lactate accumulation (PLA: 13.2±1.2; TER: 20.3±1.6 mmol kg dw(-1)) were higher (P<0.05) with TER than PLA. There was no difference between PLA and TER in net muscle glycogen utilization and lactate accumulation during the time trial. IMTG did not change with treatment or exercise. PDH-E1α Ser(293) and Ser(300) phosphorylation were lower (P<0.05) before the submaximal exercise with TER than PLA with no difference after the submaximal exercise and the time trial. Before the submaximal exercise, ACC2 Ser(221) phosphorylation was higher (P<0.05) with TER than PLA. There was no difference in αAMPK Thr(172) phosphorylation between treatments. The present study suggests that beta2-agonists do not enhance 300-kcal time trial performance, but increase carbohydrate metabolism in skeletal muscles during submaximal exercise independent of AMPK and ACC phosphorylation, and that this effect diminishes as drug exposure time, exercise duration and intensity are increased.

AB - In a randomized double-blind crossover design, we investigated the effect of the beta2-agonist terbutaline on endurance performance and substrate utilization in nine moderately trained males (maximum oxygen uptake (VO2max): 58.9±3.1 mL min(-1) kg(-1)). Subjects performed 60 min of submaximal exercise (65-70% of VO2max) immediately followed by a 300-kcal time trial with inhalation of either terbutaline (TER) or placebo (PLA). Pulmonary gas exchange was measured during the submaximal exercise and muscle biopsies were collected before and after the exercise bouts. Time trial performance was not different between PLA and TER (1054±125 vs. 1072±145 s). During the submaximal exercise, respiratory exchange ratio, glycogen breakdown (PLA: 195±28; TER: 266±32 mmol kg dw(-1)) and muscle lactate accumulation (PLA: 13.2±1.2; TER: 20.3±1.6 mmol kg dw(-1)) were higher (P<0.05) with TER than PLA. There was no difference between PLA and TER in net muscle glycogen utilization and lactate accumulation during the time trial. IMTG did not change with treatment or exercise. PDH-E1α Ser(293) and Ser(300) phosphorylation were lower (P<0.05) before the submaximal exercise with TER than PLA with no difference after the submaximal exercise and the time trial. Before the submaximal exercise, ACC2 Ser(221) phosphorylation was higher (P<0.05) with TER than PLA. There was no difference in αAMPK Thr(172) phosphorylation between treatments. The present study suggests that beta2-agonists do not enhance 300-kcal time trial performance, but increase carbohydrate metabolism in skeletal muscles during submaximal exercise independent of AMPK and ACC phosphorylation, and that this effect diminishes as drug exposure time, exercise duration and intensity are increased.

U2 - 10.1152/japplphysiol.00635.2014

DO - 10.1152/japplphysiol.00635.2014

M3 - Journal article

C2 - 25257871

VL - 117

SP - 1180

EP - 1187

JO - Journal of Applied Physiology

JF - Journal of Applied Physiology

SN - 8750-7587

IS - 10

ER -

ID: 125184588